semaglutide alzheimer's study Details of failed studies cast pall on Novo Nordisk's GLP-1 as treatment alzheimer semaglutide evoke and evoke+:

Because they determine how well your mind and body are going to work

Conclusion This case underscores the importance of integrating focal neurological deficits with headache syndromes, including rare manifestations of SIH

AOM tirzepatide prescription rates increased by an average of 0.06 percentage points a month from January 2024 to June 2025 but grew only by 0.03 percentage points between June and July

Non-aflatoxigenic strains of Aspergillus spp

Whatever the reason you came off a GLP-1 medication, you're far from alone: Within two years, nearly three in four people taking these medications for weight loss stop, according to a 2025 study of 125,000 patients